Alivus Life Sciences FY26 Revenue up 6.9% to ₹25,518 crore, EBITDA up 19.6%
Alivus Life Sciences reported FY26 revenue of ₹25,518 million, up 6.9% YoY, and EBITDA of ₹8,577 million, up 19.6% YoY. PAT rose 16.2% to ₹5,645 million, with EPS at ₹45.99. The non-GPL business grew 13%, contributing 71% of revenue. For FY27, high single-digit revenue growth and margins above 30% are projected.
The announcement includes strong financial performance metrics for the full fiscal year and quarter, positive future guidance, and strategic business segment growth (non-GPL and CDMO), which are material factors for investors and likely to impact the company's stock price.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with improved margins and EPS. The management is also confident about future growth, projecting high single-digit revenue growth and sustained margins for FY27, indicating a positive outlook.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced its financial results for the fourth quarter and full fiscal year 2026. The company reported a revenue of ₹6,891 million for Q4FY26, a 6.1% increase year-on-year. For the full fiscal year FY26, revenue grew by 6.9% year-on-year to ₹25,518 million, and EBITDA saw a significant increase of 19.6% to ₹8,577 million.
Gross margins for Q4FY26 were reported at 60.7%, up by 180 basis points quarter-on-quarter and 420 basis points year-on-year. EBITDA margins for the quarter stood at 34.4%, an increase of 230 basis points year-on-year, with FY26 EBITDA margins at 33.6%, up 360 basis points year-on-year. Profit After Tax (PAT) for FY26 was ₹5,645 million, an increase of 16.2% year-on-year, with PAT margins at 22.1% for FY26, up 180 basis points year-on-year. Earnings Per Share (EPS) for FY26 increased to ₹45.99 from ₹39.63 in FY25.
The company highlighted that its non-GPL business grew by 13% in FY26, now contributing 71% of the overall revenues. The CDMO business showed a turnaround in the second half of FY26, closing the year with 18% year-on-year growth. For FY27, Alivus is confident of delivering high single-digit revenue growth with margins sustained above 30%. The company generated a strong free cash flow of ₹2,590 million in FY26, leading to cash and cash equivalents of ₹7,824 million as of March 31, 2026. Investments in Capex are also ramped up post FY24, with significant expansion planned in Solapur and new R&D facilities.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.